Delhi HC upholds Centre decision to include all medical devices as drugs

Published On 2023-09-06 08:00 GMT | Update On 2023-09-06 08:01 GMT

Delhi High Court

New Delhi: The Delhi High Court has upheld the Centre's decision to include all medical devices within the ambit of "drug" under the law regulating drugs and cosmetics. A bench headed by Justice Rajiv Shakdher rejected petitions by the Surgical Manufacturers and Traders Association challenging the central government's 2018 and 2020 notifications first declaring four medical devices as "drugs" under the Drugs and Cosmetics Act, and then spreading the net to cover all medical devices.

The court said the decision to include all medical devices as "drugs" was a policy matter and no case for interference was made out as there was no arbitrariness or unreasonableness.

"MHFW (Ministry of Health and Family Welfare), in its wisdom, thought it fit to bring all medical devices within the ambit of the expression 'drug '. This is clearly a policy matter," the bench, also comprising Justice Tara Vitasta Ganju, said in a recent order dated September 1.

"To our minds, there is no manifest arbitrariness or unreasonableness in the shift in policy of bringing all medical devices within the ambit of a regulatory regime. Our postscript is, if we were to allow the writ petitions, figuratively speaking, we would be throwing away the baby with the bathwater," the court opined.

The authorities should, however, take measures to quickly iron out the kinks found while progressing the regulatory regime, the court said.

In 2018, the Centre had first brought four medical devices, i.e. nebuliser, blood pressure monitoring device, digital thermometer and glucometer, within the ambit of "drug". In 2020, all medical devices were notified as "drugs".

The court observed that the implementation of the policy was "calibrated" and gave ample time to the manufacturers, importers, sellers and distributors, to transition to a mandatory licensing regime.

"MHFW's reasons are manifold, which include the desire to align itself with the international regulatory regime and to further the interest of the patients. Mere errors, if any, in the policy, which is otherwise robust and devised bearing in mind patient safety, cannot be upturned by the court while exercising the power of judicial review under Article 226 of the Constitution, unless it is a clear case of demonstrable violation of fundamental rights," the court said.

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Delhi HC upholds Centre decision to include all medical devices as drugs

Similar News

Gilead Sciences gets European Commission marketing authorization for twice yearly Yeytuo for HIV prevention

Eris Lifesciences receives ANVISA approval for Ahmedabad Sterile Injectable facility

Bayer Gadoquatrane new drug application accepted for review by USFDA

Samir Desai, President-BU Biologics at Zydus Lifesciences, passes away

USFDA approves Gland Pharma Vasopressin in 5% Dextrose RTU Injection

Unichem Labs gets EIR from USFDA for Roha API facility

Biocon Pharma bags tentative USFDA nod for diabetes medicine Sitagliptin

Eris Lifesciences Slapped Rs 17 Crore GST Notice Over Novartis Zomelis Deal